|1.||Ng, T B: 4 articles (02/2009 - 03/2000)|
|2.||Ye, X Y: 3 articles (04/2001 - 03/2000)|
|3.||Lifson, Jeffrey D: 2 articles (09/2012 - 01/2008)|
|4.||Piatak, Michael: 2 articles (09/2012 - 01/2008)|
|5.||Gettie, Agegnehu: 2 articles (09/2012 - 01/2008)|
|6.||Robbiani, Melissa: 2 articles (09/2012 - 01/2008)|
|7.||Blanchard, James: 2 articles (09/2012 - 01/2008)|
|8.||Aravantinou, Meropi: 2 articles (09/2012 - 01/2008)|
|9.||Kenney, Jessica: 2 articles (09/2012 - 01/2008)|
|10.||Douglas, Steven D: 2 articles (11/2010 - 03/2007)|
|1.||HIV Infections (HIV Infection)
08/28/2008 - "Owing to the emergence of resistant virus, next generation non-nucleoside HIV reverse transcriptase inhibitors (NNRTIs) with improved drug resistance profiles have been developed to treat HIV infection. "
05/01/2015 - "Non-nucleoside inhibitors of HIV reverse transcriptase are an important component of treatment against HIV infection. "
06/01/2010 - "Following HIV infection with NL4-3 or AD8 in hepatic cell lines, we observed a significant increase in HIV reverse transcriptase activity which was infectious. "
06/01/2001 - "Inhibitors of human immunodeficiency virus (HIV) reverse transcriptase (RT) are widely used in the treatment of HIV infection. "
12/16/1996 - "Both drugs are potent inhibitors of the human immunodeficiency virus (HIV) reverse transcriptase and are used in the therapy of HIV infection. "
|2.||AIDS-Related Complex (ARC)
12/01/2014 - "HIV reverse-transcriptase drug resistance mutations during early infection reveal greater transmission diversity than in envelope sequences."
01/01/2014 - "Drugs licensed for inhibition of HIV reverse transcriptase lower the viral load of chronic HBV patients, but they do not cure the infection. "
01/01/2008 - "Since dendritic cells (DCs) are believed to be important in HIV transmission, the formulations were tested for the ability to limit DC-driven infection in vitro versus vaginal infection of macaques with RT-SHIV (SIVmac239 bearing HIV reverse transcriptase). "
03/01/2007 - "Culture supernatants were harvested for p24 enzyme-linked immunosorbent assay (ELISA) or HIV reverse transcriptase (RT) activity at different time points after infection. "
10/01/2003 - "Live MAC (infection) consistently increased HIV reverse transcriptase (RT) activity by more than 3-fold. "
|4.||Acquired Immunodeficiency Syndrome (AIDS)
10/01/2015 - "HIV reverse transcriptase gene mutations in anti-retroviral treatment naïve rural people living with HIV/AIDS."
12/01/2009 - "HIV reverse transcriptase (RT) is a primary target for drug intervention in the treatment of AIDS. "
01/01/2008 - "HIV reverse transcriptase and protease genes were sequenced and resistance mutations identified according to the International AIDS Society list. "
08/01/1999 - "Inhibitors of HIV reverse transcriptase (RT) are important drugs for the treatment of acquired immuno-deficiency syndrome (AIDS). "
04/01/1996 - "Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies."
08/01/2012 - "The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells."
02/15/2011 - "Yet none of these tested compounds have obvious inhibition against glycosidases or HIV reverse transcriptase, or show cancer cell growth inhibition."
03/01/2004 - "To test the effect of 2'-deoxyisoguanosine as a specific substrate of HIV reverse transcriptase on the growth of cultured normal and cancer cells. "
08/01/2012 - "Here, we show that the HIV reverse transcriptase inhibitor Truvada, a combination drug of the cytidine analogue emtricitabine and the adenosine analogue tenofovir, induces DNA damage and cell cycle arrest in human cancer cells. "
09/01/1998 - "beta, human immunodeficiency virus type 1 reverse transcriptase (HIV-RT), and calf thymus terminal deoxynucleotidyl transferase (TdT) in vitro, and did not influence the activities of prokaryotic DNA polymerases such as Klenow Fragment of DNA polymerase I, or the DNA-metabolic enzyme DNase I. HMI was found to be able to prevent the growth of human cancer cell lines originating from patients with leukemia or various solid tumors; its IC50 values ranged from 7.5 to 12 microM. "
|5.||Protease Inhibitors (Protease Inhibitor)
|6.||Glycoside Hydrolases (Endoglycosidases)
|7.||tenofovir disoproxil (Viread)
|8.||HIV Fusion Inhibitors
|10.||DNA-Directed DNA Polymerase (Polymerases, DNA)
|1.||Highly Active Antiretroviral Therapy (HAART)
|2.||Drug Therapy (Chemotherapy)